RxDoctor Payments Data

Carol McLennan

Nurse Practitioner · Bridgeport, WVNPI 1871969717

Payments from drug & device makers

$2,165in general payments, 2019–2025

Across 149 payments — averaging $14.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • AbbVie$545
  • Johnson & Johnson$139
  • Mallinckrodt Hospital Products Inc.$138
  • ANI Pharmaceuticals, Inc.$131
  • Pfizer$60
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$2,165100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,165 in reported general payments places this provider in the 85th percentile of 649 nurse practitioner providers in West Virginia.

See all nurse practitioner providers in West Virginia

Medicare billing

Part B allowed, 2024
$33,848
Medicare patients
160
Services billed
421

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept95$685,569
Humira(Cf) PenAdalimumab54$462,994
Xeljanz XrTofacitinib Citrate57$334,857
RinvoqUpadacitinib44$298,885
Orencia ClickjectAbatacept30$158,439
Humira(Cf)Adalimumab22$152,367
XeljanzTofacitinib Citrate16$139,726
Cosentyx SyringeSecukinumab13$134,038
EnbrelEtanercept16$123,139
Cosentyx Sensoready (2 Pens)Secukinumab11$102,210
OtezlaApremilast20$93,928
KevzaraSarilumab21$90,771
Cimzia (2 Pack)Certolizumab Pegol14$78,392
ForteoTeriparatide12$51,538
Hydroxychloroquine Sulfate285$14,821

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$545$451,25266 claims
AmgenEnbrel, Otezla$1,140$217,06836 claims
PfizerXeljanz$60$139,72616 claims
Lilly USA, LLCForteo$13$51,53812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 649 nurse practitioner providers in West Virginia.

Other nurse practitioner in Bridgeport

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →